Connection
Gregory Forlenza to Cost-Benefit Analysis
This is a "connection" page, showing publications Gregory Forlenza has written about Cost-Benefit Analysis.
|
|
Connection Strength |
|
|
|
|
|
0.044 |
|
|
|
-
Biskupiak JE, Ramos M, Levy CJ, Forlenza G, Hopley C, Boyd J, Swift D, Lamotte M, Brixner DI. Cost-effectiveness of the tubeless automated insulin delivery system vs standard of care in the management of type 1 diabetes in the United States. J Manag Care Spec Pharm. 2023 Jul; 29(7):807-817.
Score: 0.044